Small molecule · Inhibitor of galectin-3 (LGALS3) · developed by Galectin Therapeutics
Belapectin is a carbohydrate-based galectin inhibitor that binds the carbohydrate-binding domain of galectins, especially galectin-3. It is being studied in metastatic melanoma, nonalcoholic steatohepatitis, cirrhosis and prevention of esophageal varices.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04365868 | Phase 2/3 | Prevention of Esophageal Varices | Terminated | GALT |
| NCT02421094 | Phase 2 | Nonalcoholic Steatohepatitis | Completed | GALT |
| NCT02117362 | Phase 1 | Metastatic Melanoma | Completed | GALT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CirrhosisMetastatic MelanomaNASH - Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisPrevention of Esophageal Varices
See GALT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GALT catalysts and pipeline →